-
公开(公告)号：US10681932B2
公开(公告)日：2020-06-16
申请号：US15591389
申请日：2017-05-10
发明人： Claude Vincent
IPC分类号： A23L33/135 , A61K9/00 , A61P3/00 , C12N1/20 , A61P3/04 , A61K35/74 , A61K35/00 , C12R1/145 , C12R1/01 , A23P10/30 , A61K45/06
摘要： The object of the invention are compositions and medical treatment methods with an inheritable, Gram-negative, strictly anaerobic and commensal bacterium of the family Christensenellaceae belonging to an OTU (Operational Taxonomic Unit) characterized by a 16S rRNA sequence SEQ ID NO: 1 or to an OTU characterized by a 16S rRNA sequence SEQ ID NO: 2.
-
2.发明申请COMPOSITIONS AND METHODS FOR TREATING A PATHOGENIC METABOLIC CONDITION OF THE GUT MICROBIOTA AND DERIVED DISEASES 有权用于治疗胃肠微生物和衍生疾病的致病性代谢条件的组合物和方法公开(公告)号：US20160287636A1
公开(公告)日：2016-10-06
申请号：US14700462
申请日：2015-04-30
发明人： Claude Vincent
CPC分类号： A61K35/20 , A23L33/18 , A23L33/19 , A23V2002/00 , A61K31/185 , A61K31/198 , A61K31/201 , A61K31/202 , A61K31/355 , A61K31/405 , A61K31/4415 , A61K31/519 , A61K31/59 , A61K33/06 , A61K33/24 , A61K33/30 , A61K38/17 , A61K2300/00 , A23V2200/32 , A23V2200/328 , A23V2200/332 , A23V2250/54246 , A23V2250/54252
摘要： The invention relates to the use as a drug or medical nutritional product in humans to treat a pathological dysbiosis and/or to prevent or treat at least one derived metabolic disease chosen from among excess weight with comorbidity, obesity, diabetes, heart and vascular diseases, atherosclerosis, degenerative bone disease, neurodegenerative disease, metabolism-related cancers, autoimmune diseases, steatosis, metabolic steatohepatitis, and chronic inflammatory diseases of the intestine, by increasing the Christensenella bacterial genus in the intestine, of a composition comprising a mixture of active ingredients consisting of at least: a whey hydrolysate with a molecular weight comprised between 200 and 10,000 Daltons, a whey isolate and/or a concentrate, and calcium caseinate.
-
公开(公告)号：US10076553B2
公开(公告)日：2018-09-18
申请号：US14353541
申请日：2012-10-25
发明人： Claude Vincent
IPC分类号： A61K38/17 , A61K38/01 , A61K35/20 , A61K33/30 , A61K31/145 , A61K31/198 , A61K31/201 , A61K31/202 , A61K31/405 , A61K31/4415 , A61K31/519 , A61K31/59 , A61K33/06 , A61K33/24 , A23L33/18 , A23L33/19
CPC分类号： A61K38/1709 , A23L33/18 , A23L33/19 , A61K31/145 , A61K31/198 , A61K31/201 , A61K31/202 , A61K31/405 , A61K31/4415 , A61K31/519 , A61K31/59 , A61K33/06 , A61K33/24 , A61K33/30 , A61K35/20 , A61K38/018 , A61K2300/00
摘要： A dietary product for preventing cardiometabolic risk in humans, in particular for reducing visceral fat and deep subcutaneous fat, includes in particular a mixture of: a whey hydrolysate having a molecular weight of between 200 and 10,000 daltons, an isolate and/or concentrate of whey, and calcium caseinate.
-
公开(公告)号：US09616092B2
公开(公告)日：2017-04-11
申请号：US14700462
申请日：2015-04-30
发明人： Claude Vincent
IPC分类号： A01N65/00 , A61K35/20 , A23L1/305 , A61K38/17 , A61K31/198 , A61K31/202 , A61K31/355 , A61K31/405 , A61K31/4415 , A61K31/519 , A61K31/59 , A61K33/06 , A61K33/24 , A61K33/30
CPC分类号： A61K35/20 , A23L33/18 , A23L33/19 , A23V2002/00 , A61K31/185 , A61K31/198 , A61K31/201 , A61K31/202 , A61K31/355 , A61K31/405 , A61K31/4415 , A61K31/519 , A61K31/59 , A61K33/06 , A61K33/24 , A61K33/30 , A61K38/17 , A61K2300/00 , A23V2200/32 , A23V2200/328 , A23V2200/332 , A23V2250/54246 , A23V2250/54252
摘要： The invention relates to the use as a drug or medical nutritional product in humans to treat a pathological dysbiosis and/or to prevent or treat at least one derived metabolic disease chosen from among excess weight with comorbidity, obesity, diabetes, heart and vascular diseases, atherosclerosis, degenerative bone disease, neurodegenerative disease, metabolism-related cancers, autoimmune diseases, steatosis, metabolic steatohepatitis, and chronic inflammatory diseases of the intestine, by increasing the Christensenella bacterial genus in the intestine, of a composition comprising a mixture of active ingredients consisting of at least: a whey hydrolysate with a molecular weight comprised between 200 and 10,000 Daltons, a whey isolate and/or a concentrate, and calcium caseinate.
-
5.发明申请公开(公告)号：US20140308369A1
公开(公告)日：2014-10-16
申请号：US14353605
申请日：2012-10-25
发明人： Claude Vincent
IPC分类号： A61K38/17 , A61K31/198 , A61K31/405 , A61K31/185 , A61K33/06 , A61K33/30 , A61K31/59 , A61K31/519 , A61K31/355 , A61K33/24 , A61K31/675 , A61K31/202 , A23L1/305 , A23L2/66 , A61K38/01
CPC分类号： A61K38/1709 , A23L2/66 , A23L33/18 , A23L33/19 , A23V2002/00 , A61K31/185 , A61K31/198 , A61K31/202 , A61K31/355 , A61K31/405 , A61K31/519 , A61K31/59 , A61K31/675 , A61K33/06 , A61K33/24 , A61K33/30 , A61K38/011
摘要： An orally administered dietary product intended to reduce an obese person's visceral fat during the pre-operative phase prior to bariatric surgery, the product includes in particular a mixture of: a whey hydrolysate having a molecular weight of between 200 and 10,000 daltons, an isolate and/or a concentrate of whey, and calcium caseinate.
摘要翻译： 口服给药的饮食产品旨在在减肥手术之前的术前期间减少肥胖者的内脏脂肪，该产品特别包括以下混合物：分子量为200至10,000道尔顿的乳清水解产物，分离物和 /或乳清浓缩物和酪蛋白酸钙。
-
公开(公告)号：US11044933B2
公开(公告)日：2021-06-29
申请号：US15933015
申请日：2018-03-22
发明人： Claude Vincent
IPC分类号： A61K35/741 , A23L33/135 , A61K9/00 , C12R1/145 , A61P3/00 , C12N1/20 , A61P3/04 , C12R1/01 , A23P10/30 , A61K35/74 , A61K35/00 , A61K45/06
摘要： The object of the invention are compositions and medical treatment methods with an inheritable, Gram-negative, strictly anaerobic and commensal bacterium of the family Christensenellaceae belonging to an OTU (Operational Taxonomic Unit) characterized by a 16S rRNA sequence SEQ ID NO: 1 or to an OTU characterized by a16S rRNA sequence SEQ ID NO: 2.
-
公开(公告)号：US20180255821A1
公开(公告)日：2018-09-13
申请号：US15933015
申请日：2018-03-22
发明人： Claude Vincent
IPC分类号： A23L33/135 , A61K35/74
CPC分类号： A23L33/135 , A23P10/30 , A61K9/00 , A61K9/0053 , A61K35/00 , A61K35/74 , A61K45/06 , A61K2035/11 , A61P3/00 , A61P3/04 , C12N1/20 , C12R1/01 , C12R1/145
摘要： The object of the invention are compositions and medical treatment methods with an inheritable, Gram-negative, strictly anaerobic and commensal bacterium of the family Christensenellaceae belonging to an OTU (Operational Taxonomic Unit) characterized by a 16S rRNA sequence SEQ ID NO: 1 or to an OTU characterized by a165 rRNA sequence SEQ ID NO: 2.
-
8.发明申请COMPOSITIONS COMPRISING PLANT PROTEINS AND METHODS FOR PREVENTION OF METABOLIC AND CARDIOVASCULAR PATHOLOGIES IN PATIENT WITH CARDIOMETABOLIC RISK, INCLUDING HYPERGLYCEMIA 审中-公开包含植物蛋白的组合物和用于预防患有代谢性和心脏病的病人的心脏病风险的方法，包括高血压公开(公告)号：US20160114002A1
公开(公告)日：2016-04-28
申请号：US14549709
申请日：2014-11-21
发明人： Claude Vincent
IPC分类号： A61K38/38 , A23L1/303 , A23L1/304 , A23L2/52 , A23L2/66 , A23L1/302 , A61K38/16 , A61K38/17 , A61K31/202 , A61K31/405 , A61K31/185 , A61K31/121 , A61K47/10 , A61K47/24 , A61K47/22 , A61K47/02 , A61K31/198 , A23L1/305
CPC分类号： A61K38/38 , A23L2/52 , A23L2/66 , A23L33/10 , A23L33/12 , A23L33/15 , A23L33/155 , A23L33/16 , A23L33/17 , A23L33/175 , A23L33/185 , A23L33/19 , A23V2002/00 , A61K31/121 , A61K31/185 , A61K31/198 , A61K31/202 , A61K31/405 , A61K38/168 , A61K38/1709 , A61K47/02 , A61K47/10 , A61K47/22 , A61K47/24 , A23V2200/326
摘要： A composition for oral administration in humans comprising at least one plant protein chosen from pea proteins, rice proteins or a mixture thereof, and: at least one protein of animal origin chosen from calcium caseinate, lactoserum proteins, or a mixture thereof, and/or at least one free amino acid chosen from leucine, glutamine, isoleucine, valine, tryptophan or plant 5HTP, lysine, threonine, arginine and taurine, or any mixture thereof, and/or at least one micronutrient chosen from vitamin D, vitamin B6, vitamin B9, vitamin E, milk calcium, marine magnesium, zinc and chromium, or any mixture thereof, and/or at least one anti-inflammatory and/or antioxidant compound of plant origin chosen from ALA omega-3 fatty acid, purified EPA, protectin in PD1 or PDX form, and curcumin, or any mixture thereof. Methods with these compositions for preventing cardiometabolic risk are also provided.
摘要翻译： 一种用于人类口服给药的组合物，其包含至少一种选自豌豆蛋白，水稻蛋白质或其混合物的植物蛋白质，和至少一种选自酪蛋白酸钙，乳糖蛋白质或其混合物的动物来源的蛋白质，和/或 选自亮氨酸，谷氨酰胺，异亮氨酸，缬氨酸，色氨酸或植物5HTP，赖氨酸，苏氨酸，精氨酸和牛磺酸或其任何混合物中的至少一种游离氨基酸和/或选自维生素D，维生素B6，维生素 B9，维生素E，乳钙，海洋镁，锌和铬或其任何混合物，和/或至少一种选自ALAω-3脂肪酸，纯化的EPA，保护素的植物来源的抗炎和/或抗氧化剂化合物 PD1或PDX形式，以及姜黄素或其任何混合物。 还提供了用于预防心脏代谢风险的这些组合物的方法。
-
公开(公告)号：US20140287057A1
公开(公告)日：2014-09-25
申请号：US14353541
申请日：2012-10-25
发明人： Claude Vincent
IPC分类号： A61K38/17 , A61K31/4415 , A61K33/30 , A61K31/145 , A61K33/24 , A61K31/201 , A61K31/59 , A61K31/202 , A61K31/198 , A61K31/405 , A61K33/06 , A61K35/20 , A61K31/519
CPC分类号： A61K38/1709 , A23L33/18 , A23L33/19 , A61K31/145 , A61K31/198 , A61K31/201 , A61K31/202 , A61K31/405 , A61K31/4415 , A61K31/519 , A61K31/59 , A61K33/06 , A61K33/24 , A61K33/30 , A61K35/20 , A61K38/018 , A61K2300/00
摘要： A dietary product for preventing cardiometabolic risk in humans, in particular for reducing visceral fat and deep subcutaneous fat, includes in particular a mixture of: a whey hydrolysate having a molecular weight of between 200 and 10,000 daltons, an isolate and/or concentrate of whey, and calcium caseinate.
摘要翻译： 用于预防人类心脏代谢风险的膳食产品，特别是用于减少内脏脂肪和深层皮下脂肪的膳食产品尤其包括：分子量为200至10,000道尔顿的乳清水解产物，乳清分离物和/或浓缩物的混合物 ，和酪蛋白酸钙。
-
公开(公告)号：US20210352946A1
公开(公告)日：2021-11-18
申请号：US17331776
申请日：2021-05-27
发明人： Claude Vincent
IPC分类号： A23L33/135 , A61K9/00 , A61P3/00 , C12N1/20 , A61P3/04 , A61K35/741 , A23P10/30 , A61K35/74
摘要： The object of the invention are compositions and medical treatment methods with an inheritable, Gram-negative, strictly anaerobic and commensal bacterium of the family Christensenellaceae belonging to an OTU (Operational Taxonomic Unit) characterized by a 16S rRNA sequence SEQ ID NO: 1 or to an OTU characterized by a 16S rRNA sequence SEQ ID NO: 2.
-
-
-
-
-
-
-
-
-
搜索结果
15 条记录 (耗时 0.018 秒)
